Jim Simons
BRTX icon

Jim Simons’s BioRestorative Therapies BRTX Stock Holding History

Jim Simons’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$34.8K – 3583
2024
Q3 		$34.8K Buy
+20,000
New +$32.9K ﹤0.01% 3384
2024
Q2 		– Sell
-24,861
Closed -$34K – 3519
2024
Q1 		$34K Buy
+24,861
New +$38.3K ﹤0.01% 3538

Other funds holding BRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UFA
US Financial Advisors Braintree, Massachusetts $338M AUM 4.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

Jim Simons's BRTX Position: Q4 2024 in Review

Jim Simons sold out of BioRestorative Therapies (BRTX) in Q4 2024, closing a stake of 20,000 shares — an estimated $34.8K sold.

Jim Simons first reported a position in BRTX in Q1 2024 and held it in 2 quarters. The position peaked at $34.8K in Q3 2024. 15 funds tracked by Wall St. Rank hold BRTX as of Q4 2024.

  • Jim Simons reported no remaining BioRestorative Therapies position as of Q4 2024 after selling out during the quarter.
  • Jim Simons sold 20,000 BioRestorative Therapies shares in Q4 2024, an estimated $34.8K.
  • Jim Simons first reported a position in BioRestorative Therapies in Q1 2024 and held it in 2 quarters.
  • Jim Simons's BioRestorative Therapies position peaked at $34.8K in Q3 2024.
  • 15 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.